<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03413618</url>
  </required_header>
  <id_info>
    <org_study_id>RIDILOTT-DVT</org_study_id>
    <nct_id>NCT03413618</nct_id>
  </id_info>
  <brief_title>Rivaroxaban With Diosmin in Long-term Treatment of Deep Vein Thrombosis</brief_title>
  <acronym>RIDILOTT-DVT</acronym>
  <official_title>The Efficacy of Rivaroxaban With Diosmin in the Long-term Treatment of Acute Proximal Deep Vein Thrombosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pirogov Russian National Research Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pirogov Russian National Research Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The randomized clinical study aimed to assess the efficacy and safety of standard
      anticoagulation with rivaroxaban in combination with diosmin compared to the isolated use of
      standard rivaroxaban for prolonged therapy of acute femoro-popliteal deep vein thrombosis
      reflected the speed of deep vein recanalization and incidence of post-thrombotic syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Deep vein thrombosis is an acute inflammatory disease that affects vein wall and leads to the
      structural changes in the wall and valves reflected with chronic venous insufficiency that
      called postthrombotic syndrome (PTS).

      Diosmin as a flavonoid agent has properties to reduce leukocyte-endothelial interaction and
      inflammatory response, that could reduce the damage to venous wall and valves.

      The hypothesis of the study is based on assumption that diosmin combined with standard
      anticoagulation can improve outcomes of femoro-popliteal DVT due to increase speed of veins
      recanalization, decrease of vein wall inflammation and finally decrease the incidence of PTS
      at 6 month and 1 year after index DVT.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 20, 2017</start_date>
  <completion_date type="Actual">July 31, 2019</completion_date>
  <primary_completion_date type="Actual">July 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized open-labeled clinical trial with a masked outcomes assessor</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Outcomes assessor does not involve in randomisation and treatment process, has no information about the patient's belonging to one of the study groups</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Postthrombotic Syndrome as Determined by Villalta Score</measure>
    <time_frame>12 months</time_frame>
    <description>Detection of the postthrombotic syndrome (PTS) was made according to the Villalta score (a combination of 5 subjective symptoms and 6 objective signs of chronic venous disease) ranged from 0 (no signs) to 33 scores (maximal severity). PTS defined as 5 and more scores; mild PTS as 5-9 scores; moderate PTS as 10-14 scores; severe PTS as 15 and more scores.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Recurrent Symptomatic or Asymptomatic DVT</measure>
    <time_frame>12 months</time_frame>
    <description>detection of any episode of recurrent DVT with or without clinical signs verified by duplex ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Symptomatic Pulmonary Embolism</measure>
    <time_frame>12 months</time_frame>
    <description>detection of symptomatic pulmonary embolism verified with CT pulmonary angiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Value of Venous Clinical Severity Score</measure>
    <time_frame>12 months</time_frame>
    <description>Venous Clinical Severity Score (VCSS) is a combination of subjective symptoms and objective signs of CVD aimed to assess the severity of disease and ranges from 0 (no signs and symptoms of CVD) to 30 (severe signs and symptoms of CVD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Value of Chronic Lower Limb Venous Insufficiency Questionnaire - 20 Items</measure>
    <time_frame>12 months</time_frame>
    <description>Chronic Lower Limb Venous Insufficiency Questionnaire - 20 items (CIVIQ-20) is a venous specific questionnaire to assess the disease-specific quality of life (QoL). It contains 20 items of 1-5 scores, totally, from 20 (best QoL) to100 (worst QoL) scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Full Recanalization of the Popliteal Vein</measure>
    <time_frame>12 months</time_frame>
    <description>Full recanalization of popliteal vein suggests the residual venous obstruction (RVO) less than 20%. The RVO was assessed by duplex ultrasound and calculated as the vein cross-sectional diameter under the maximal compression divided on the diameter without any compression multiplied by 100%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extension of Residual Venous Obstruction by Marder Score</measure>
    <time_frame>12 months</time_frame>
    <description>Residual venous obstruction (RVO) defined as a thrombotic masses occupying 20% and more of the vein cross-sectional diameter was measured by duplex ultrasound and calculated as the vein cross-sectional diameter under the maximal compression divided on the diameter without compression and multiplied by 100%. The extension of RVO was assessed by Marder score, the sum of all affected venous segments, evaluated by different scores (see Appendix of the Protocol), that ranged from 0 (no RVO) to 34 (RVO in all possible venous segments in one limb).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>any adverse events detected or suspected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Bleeding</measure>
    <time_frame>12 months</time_frame>
    <description>according to the International Society of Thrombosis and Hemostasis (ISTH) definition, major bleeding defined as fatal bleeding, and/or symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome, and/or bleeding causing a fall in hemoglobin level of 20 g/L or 1.24 mmol/L or more, or leading to transfusion of two or more units of whole blood or red cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically Relevant Non-major Bleeding</measure>
    <time_frame>12 months</time_frame>
    <description>any non-major bleeding requiring anticoagulant withdrawal, and/or performing haemostatic measures, and/or hospitalization, and/or an unscheduled medical appointment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minor Bleeding</measure>
    <time_frame>12 months</time_frame>
    <description>any non-major or non-clinically relevant bleeding does not require the suspension of therapy and changes in the patient's lifestyle</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Deep Vein Thrombosis</condition>
  <condition>Postthrombotic Syndrome</condition>
  <arm_group>
    <arm_group_label>Experimental: Rivaroxaban + Diosmin + Stockings</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treatment of deep vein thrombosis with anticoagulation (rivaroxaban), elastic compression stockings and additional prescription of diosmin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control: Rivaroxaban + Stockings only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard treatment of deep vein thrombosis with anticoagulation (rivaroxaban) and elastic compression stockings</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>15 mg b.i.d. for 3 weeks and then 20 mg q.d. up to 6 month</description>
    <arm_group_label>Control: Rivaroxaban + Stockings only</arm_group_label>
    <arm_group_label>Experimental: Rivaroxaban + Diosmin + Stockings</arm_group_label>
    <other_name>xarelto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diosmin</intervention_name>
    <description>600 mg q.d. for 12 month</description>
    <arm_group_label>Experimental: Rivaroxaban + Diosmin + Stockings</arm_group_label>
    <other_name>flebodia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>compression stockings</intervention_name>
    <description>above knee stocking for 12 month</description>
    <arm_group_label>Control: Rivaroxaban + Stockings only</arm_group_label>
    <arm_group_label>Experimental: Rivaroxaban + Diosmin + Stockings</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age over 18 years

          -  The first episode of femoro-popliteal deep vein thrombosis (DVT)

          -  Verification of DVT by duplex ultrasound

          -  Informed consent signed

        Exclusion Criteria:

          -  Suspicion of pulmonary embolism (PE)

          -  Verified PE

          -  Bilateral DVT

          -  Contraindications for rivaroxaban (in accordance with the official instructions)

          -  Contraindications for diosmin (in accordance with the official instructions)

          -  Active cancer

          -  Verified severe thrombophilia (antiphospholipid antibodies, deficiency of proteins C,
             S, antithrombin 3)

          -  Use of other anticoagulants for more than 7 days from the DVT verification

          -  Impossibility of using compression stocking after 3 days from DVT verification

          -  Performed surgical intervention on the superficial or deep veins of the lower
             extremities (thrombolysis, thrombectomy, vein ligation, implantation of the inferior
             cava filter)

          -  Continuous use of other drugs that affect the hemostasis system (except for
             acetylsalicylic acid in a dose of not more than 100 mg).

          -  Low compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ilya Schastlivtsev, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pirogov Russian National Research Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Hospital no.1 of the President's Administration of Russian Federation</name>
      <address>
        <city>Moscow</city>
        <zip>121352</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>January 18, 2018</study_first_submitted>
  <study_first_submitted_qc>January 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2018</study_first_posted>
  <results_first_submitted>May 13, 2019</results_first_submitted>
  <results_first_submitted_qc>January 14, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 27, 2020</results_first_posted>
  <last_update_submitted>January 14, 2020</last_update_submitted>
  <last_update_submitted_qc>January 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>deep vein thrombosis</keyword>
  <keyword>postthrombotic syndrome</keyword>
  <keyword>anticoagulation</keyword>
  <keyword>treatment</keyword>
  <keyword>prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
    <mesh_term>Postthrombotic Syndrome</mesh_term>
    <mesh_term>Postphlebitic Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 11, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/18/NCT03413618/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Admitted to the hospital with the suspicion for DVT: 202; DVT verified: 158; Eligible DVT: 102; Rejected to participate: 12; Randomized: 90</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Experimental: Rivaroxaban + Diosmin + Stockings</title>
          <description>treatment of DVT with anticoagulation (rivaroxaban), elastic compression stockings and additional prescription of diosmin
Rivaroxaban: 15 mg b.i.d. for 3 weeks and then 20 mg q.d. up to 6 month
Diosmin: 600 mg q.d. for 12 month
compression stockings: above knee stocking for 12 month</description>
        </group>
        <group group_id="P2">
          <title>Control: Rivaroxaban + Stockings Only</title>
          <description>standard treatment of DVT with anticoagulation (rivaroxaban) and elastic compression stockings
Rivaroxaban: 15 mg b.i.d. for 3 weeks and then 20 mg q.d. up to 6 month
compression stockings: above knee stocking for 12 month</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Experimental: Rivaroxaban + Diosmin + Stocking</title>
          <description>treatment of DVT with anticoagulation (rivaroxaban), elastic compression stockings and additional prescription of diosmin
Rivaroxaban: 15 mg b.i.d. for 3 weeks and then 20 mg q.d. up to 6 month
Diosmin: 600 mg q.d. for 12 month
compression stockings: above knee stocking for 12 month</description>
        </group>
        <group group_id="B2">
          <title>Control: Rivaroxaban + Stockings Only</title>
          <description>standard treatment of DVT with anticoagulation (rivaroxaban) and elastic compression stockings
Rivaroxaban: 15 mg b.i.d. for 3 weeks and then 20 mg q.d. up to 6 month
compression stockings: above knee stocking for 12 month</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
            <count group_id="B2" value="45"/>
            <count group_id="B3" value="90"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="45"/>
                    <count group_id="B2" value="45"/>
                    <count group_id="B3" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.4" spread="13.8"/>
                    <measurement group_id="B2" value="60.2" spread="13.1"/>
                    <measurement group_id="B3" value="58.8" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="45"/>
                    <count group_id="B2" value="45"/>
                    <count group_id="B3" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Russia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="45"/>
                    <count group_id="B2" value="45"/>
                    <count group_id="B3" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time to randomization</title>
          <description>Number of days from DVT verification to randomization</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="45"/>
                    <count group_id="B2" value="45"/>
                    <count group_id="B3" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.4" spread="1.2"/>
                    <measurement group_id="B2" value="3.5" spread="1.6"/>
                    <measurement group_id="B3" value="3.5" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Unprovoked DVT</title>
          <description>DVT without any identified clinical provocation (e.g. major surgery, trauma, immobilization, pregnancy and postpartum, estrogen-containing pills, long-travel, etc)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="45"/>
                    <count group_id="B2" value="45"/>
                    <count group_id="B3" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Preexisting chronic venous disease</title>
          <description>Chronic venous disease (CVD) according to the Clinical-Etiology-Anatomy-Pathophysiology (CEAP) clinical class: C0 - no signs for CVD; C1 - telangiectasia and reticular veins; C2 - varicose veins; C3 - venous edema; C4 - skin pigmentation, induration, venous eczema of skin white atrophy; C5 - healed venous ulcer; C6 - active venous ulcer. Preexisting CVD suggests C2 and higher CEAP clinical class.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="45"/>
                    <count group_id="B2" value="45"/>
                    <count group_id="B3" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Thrombus burden</title>
          <description>Extension of DVT assessed with duplex ultrasound by Marder score (see Appendix 1 to the Protocol): ranges from 0 (no thrombus) to 34 (occlusion of all veins in one limb).</description>
          <units>Marder score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="45"/>
                    <count group_id="B2" value="45"/>
                    <count group_id="B3" value="90"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.2" spread="4.7"/>
                    <measurement group_id="B2" value="11.6" spread="4.1"/>
                    <measurement group_id="B3" value="13.4" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Postthrombotic Syndrome as Determined by Villalta Score</title>
        <description>Detection of the postthrombotic syndrome (PTS) was made according to the Villalta score (a combination of 5 subjective symptoms and 6 objective signs of chronic venous disease) ranged from 0 (no signs) to 33 scores (maximal severity). PTS defined as 5 and more scores; mild PTS as 5-9 scores; moderate PTS as 10-14 scores; severe PTS as 15 and more scores.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental: Rivaroxaban + Diosmin + Stockings</title>
            <description>treatment of DVT with anticoagulation (rivaroxaban), elastic compression stockings and additional prescription of diosmin
Rivaroxaban: 15 mg b.i.d. for 3 weeks and then 20 mg q.d. up to 6 month
Diosmin: 600 mg q.d. for 12 month
compression stockings: above knee stocking for 12 month</description>
          </group>
          <group group_id="O2">
            <title>Control: Rivaroxaban + Stockings Only</title>
            <description>standard treatment of DVT with anticoagulation (rivaroxaban) and elastic compression stockings
Rivaroxaban: 15 mg b.i.d. for 3 weeks and then 20 mg q.d. up to 6 month
compression stockings: above knee stocking for 12 month</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Postthrombotic Syndrome as Determined by Villalta Score</title>
          <description>Detection of the postthrombotic syndrome (PTS) was made according to the Villalta score (a combination of 5 subjective symptoms and 6 objective signs of chronic venous disease) ranged from 0 (no signs) to 33 scores (maximal severity). PTS defined as 5 and more scores; mild PTS as 5-9 scores; moderate PTS as 10-14 scores; severe PTS as 15 and more scores.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Recurrent Symptomatic or Asymptomatic DVT</title>
        <description>detection of any episode of recurrent DVT with or without clinical signs verified by duplex ultrasound</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental: Rivaroxaban + Diosmin + Stockings</title>
            <description>treatment of DVT with anticoagulation (rivaroxaban), elastic compression stockings and additional prescription of diosmin
Rivaroxaban: 15 mg b.i.d. for 3 weeks and then 20 mg q.d. up to 6 month
Diosmin: 600 mg q.d. for 12 month
compression stockings: above knee stocking for 12 month</description>
          </group>
          <group group_id="O2">
            <title>Control: Rivaroxaban + Stockings Only</title>
            <description>standard treatment of DVT with anticoagulation (rivaroxaban) and elastic compression stockings
Rivaroxaban: 15 mg b.i.d. for 3 weeks and then 20 mg q.d. up to 6 month
compression stockings: above knee stocking for 12 month</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Recurrent Symptomatic or Asymptomatic DVT</title>
          <description>detection of any episode of recurrent DVT with or without clinical signs verified by duplex ultrasound</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.049</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Symptomatic Pulmonary Embolism</title>
        <description>detection of symptomatic pulmonary embolism verified with CT pulmonary angiogram</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental: Rivaroxaban + Diosmin + Stockings</title>
            <description>treatment of DVT with anticoagulation (rivaroxaban), elastic compression stockings and additional prescription of diosmin
Rivaroxaban: 15 mg b.i.d. for 3 weeks and then 20 mg q.d. up to 6 month
Diosmin: 600 mg q.d. for 12 month
compression stockings: above knee stocking for 12 month</description>
          </group>
          <group group_id="O2">
            <title>Control: Rivaroxaban + Stockings Only</title>
            <description>standard treatment of DVT with anticoagulation (rivaroxaban) and elastic compression stockings
Rivaroxaban: 15 mg b.i.d. for 3 weeks and then 20 mg q.d. up to 6 month
compression stockings: above knee stocking for 12 month</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Symptomatic Pulmonary Embolism</title>
          <description>detection of symptomatic pulmonary embolism verified with CT pulmonary angiogram</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Value of Venous Clinical Severity Score</title>
        <description>Venous Clinical Severity Score (VCSS) is a combination of subjective symptoms and objective signs of CVD aimed to assess the severity of disease and ranges from 0 (no signs and symptoms of CVD) to 30 (severe signs and symptoms of CVD)</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental: Rivaroxaban + Diosmin + Stockings</title>
            <description>treatment of DVT with anticoagulation (rivaroxaban), elastic compression stockings and additional prescription of diosmin
Rivaroxaban: 15 mg b.i.d. for 3 weeks and then 20 mg q.d. up to 6 month
Diosmin: 600 mg q.d. for 12 month
compression stockings: above knee stocking for 12 month</description>
          </group>
          <group group_id="O2">
            <title>Control: Rivaroxaban + Stockings Only</title>
            <description>standard treatment of DVT with anticoagulation (rivaroxaban) and elastic compression stockings
Rivaroxaban: 15 mg b.i.d. for 3 weeks and then 20 mg q.d. up to 6 month
compression stockings: above knee stocking for 12 month</description>
          </group>
        </group_list>
        <measure>
          <title>The Value of Venous Clinical Severity Score</title>
          <description>Venous Clinical Severity Score (VCSS) is a combination of subjective symptoms and objective signs of CVD aimed to assess the severity of disease and ranges from 0 (no signs and symptoms of CVD) to 30 (severe signs and symptoms of CVD)</description>
          <units>VCSS score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="1.1"/>
                    <measurement group_id="O2" value="4.4" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Value of Chronic Lower Limb Venous Insufficiency Questionnaire - 20 Items</title>
        <description>Chronic Lower Limb Venous Insufficiency Questionnaire - 20 items (CIVIQ-20) is a venous specific questionnaire to assess the disease-specific quality of life (QoL). It contains 20 items of 1-5 scores, totally, from 20 (best QoL) to100 (worst QoL) scores.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental: Rivaroxaban + Diosmin + Stockings</title>
            <description>treatment of DVT with anticoagulation (rivaroxaban), elastic compression stockings and additional prescription of diosmin
Rivaroxaban: 15 mg b.i.d. for 3 weeks and then 20 mg q.d. up to 6 month
Diosmin: 600 mg q.d. for 12 month
compression stockings: above knee stocking for 12 month</description>
          </group>
          <group group_id="O2">
            <title>Control: Rivaroxaban + Stockings Only</title>
            <description>standard treatment of DVT with anticoagulation (rivaroxaban) and elastic compression stockings
Rivaroxaban: 15 mg b.i.d. for 3 weeks and then 20 mg q.d. up to 6 month
compression stockings: above knee stocking for 12 month</description>
          </group>
        </group_list>
        <measure>
          <title>The Value of Chronic Lower Limb Venous Insufficiency Questionnaire - 20 Items</title>
          <description>Chronic Lower Limb Venous Insufficiency Questionnaire - 20 items (CIVIQ-20) is a venous specific questionnaire to assess the disease-specific quality of life (QoL). It contains 20 items of 1-5 scores, totally, from 20 (best QoL) to100 (worst QoL) scores.</description>
          <units>CIVIQ-20 scores</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.1" spread="3.3"/>
                    <measurement group_id="O2" value="28.8" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Full Recanalization of the Popliteal Vein</title>
        <description>Full recanalization of popliteal vein suggests the residual venous obstruction (RVO) less than 20%. The RVO was assessed by duplex ultrasound and calculated as the vein cross-sectional diameter under the maximal compression divided on the diameter without any compression multiplied by 100%.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental: Rivaroxaban + Diosmin + Stockings</title>
            <description>treatment of DVT with anticoagulation (rivaroxaban), elastic compression stockings and additional prescription of diosmin
Rivaroxaban: 15 mg b.i.d. for 3 weeks and then 20 mg q.d. up to 6 month
Diosmin: 600 mg q.d. for 12 month
compression stockings: above knee stocking for 12 month</description>
          </group>
          <group group_id="O2">
            <title>Control: Rivaroxaban + Stockings Only</title>
            <description>standard treatment of DVT with anticoagulation (rivaroxaban) and elastic compression stockings
Rivaroxaban: 15 mg b.i.d. for 3 weeks and then 20 mg q.d. up to 6 month
compression stockings: above knee stocking for 12 month</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Full Recanalization of the Popliteal Vein</title>
          <description>Full recanalization of popliteal vein suggests the residual venous obstruction (RVO) less than 20%. The RVO was assessed by duplex ultrasound and calculated as the vein cross-sectional diameter under the maximal compression divided on the diameter without any compression multiplied by 100%.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Extension of Residual Venous Obstruction by Marder Score</title>
        <description>Residual venous obstruction (RVO) defined as a thrombotic masses occupying 20% and more of the vein cross-sectional diameter was measured by duplex ultrasound and calculated as the vein cross-sectional diameter under the maximal compression divided on the diameter without compression and multiplied by 100%. The extension of RVO was assessed by Marder score, the sum of all affected venous segments, evaluated by different scores (see Appendix of the Protocol), that ranged from 0 (no RVO) to 34 (RVO in all possible venous segments in one limb).</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental: Rivaroxaban + Diosmin + Stockings</title>
            <description>treatment of DVT with anticoagulation (rivaroxaban), elastic compression stockings and additional prescription of diosmin
Rivaroxaban: 15 mg b.i.d. for 3 weeks and then 20 mg q.d. up to 6 month
Diosmin: 600 mg q.d. for 12 month
compression stockings: above knee stocking for 12 month</description>
          </group>
          <group group_id="O2">
            <title>Control: Rivaroxaban + Stockings Only</title>
            <description>standard treatment of DVT with anticoagulation (rivaroxaban) and elastic compression stockings
Rivaroxaban: 15 mg b.i.d. for 3 weeks and then 20 mg q.d. up to 6 month
compression stockings: above knee stocking for 12 month</description>
          </group>
        </group_list>
        <measure>
          <title>Extension of Residual Venous Obstruction by Marder Score</title>
          <description>Residual venous obstruction (RVO) defined as a thrombotic masses occupying 20% and more of the vein cross-sectional diameter was measured by duplex ultrasound and calculated as the vein cross-sectional diameter under the maximal compression divided on the diameter without compression and multiplied by 100%. The extension of RVO was assessed by Marder score, the sum of all affected venous segments, evaluated by different scores (see Appendix of the Protocol), that ranged from 0 (no RVO) to 34 (RVO in all possible venous segments in one limb).</description>
          <units>Marder score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="1.0"/>
                    <measurement group_id="O2" value="1.9" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>any adverse events detected or suspected</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental: Rivaroxaban + Diosmin + Stockings</title>
            <description>treatment of DVT with anticoagulation (rivaroxaban), elastic compression stockings and additional prescription of diosmin
Rivaroxaban: 15 mg b.i.d. for 3 weeks and then 20 mg q.d. up to 6 month
Diosmin: 600 mg q.d. for 12 month
compression stockings: above knee stocking for 12 month</description>
          </group>
          <group group_id="O2">
            <title>Control: Rivaroxaban + Stockings Only</title>
            <description>standard treatment of DVT with anticoagulation (rivaroxaban) and elastic compression stockings
Rivaroxaban: 15 mg b.i.d. for 3 weeks and then 20 mg q.d. up to 6 month
compression stockings: above knee stocking for 12 month</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>any adverse events detected or suspected</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.000</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Bleeding</title>
        <description>according to the International Society of Thrombosis and Hemostasis (ISTH) definition, major bleeding defined as fatal bleeding, and/or symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome, and/or bleeding causing a fall in hemoglobin level of 20 g/L or 1.24 mmol/L or more, or leading to transfusion of two or more units of whole blood or red cells</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental: Rivaroxaban + Diosmin + Stockings</title>
            <description>treatment of DVT with anticoagulation (rivaroxaban), elastic compression stockings and additional prescription of diosmin
Rivaroxaban: 15 mg b.i.d. for 3 weeks and then 20 mg q.d. up to 6 month
Diosmin: 600 mg q.d. for 12 month
compression stockings: above knee stocking for 12 month</description>
          </group>
          <group group_id="O2">
            <title>Control: Rivaroxaban + Stockings Only</title>
            <description>standard treatment of DVT with anticoagulation (rivaroxaban) and elastic compression stockings
Rivaroxaban: 15 mg b.i.d. for 3 weeks and then 20 mg q.d. up to 6 month
compression stockings: above knee stocking for 12 month</description>
          </group>
        </group_list>
        <measure>
          <title>Major Bleeding</title>
          <description>according to the International Society of Thrombosis and Hemostasis (ISTH) definition, major bleeding defined as fatal bleeding, and/or symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome, and/or bleeding causing a fall in hemoglobin level of 20 g/L or 1.24 mmol/L or more, or leading to transfusion of two or more units of whole blood or red cells</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinically Relevant Non-major Bleeding</title>
        <description>any non-major bleeding requiring anticoagulant withdrawal, and/or performing haemostatic measures, and/or hospitalization, and/or an unscheduled medical appointment</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental: Rivaroxaban + Diosmin + Stockings</title>
            <description>treatment of DVT with anticoagulation (rivaroxaban), elastic compression stockings and additional prescription of diosmin
Rivaroxaban: 15 mg b.i.d. for 3 weeks and then 20 mg q.d. up to 6 month
Diosmin: 600 mg q.d. for 12 month
compression stockings: above knee stocking for 12 month</description>
          </group>
          <group group_id="O2">
            <title>Control: Rivaroxaban + Stockings Only</title>
            <description>standard treatment of DVT with anticoagulation (rivaroxaban) and elastic compression stockings
Rivaroxaban: 15 mg b.i.d. for 3 weeks and then 20 mg q.d. up to 6 month
compression stockings: above knee stocking for 12 month</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Relevant Non-major Bleeding</title>
          <description>any non-major bleeding requiring anticoagulant withdrawal, and/or performing haemostatic measures, and/or hospitalization, and/or an unscheduled medical appointment</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minor Bleeding</title>
        <description>any non-major or non-clinically relevant bleeding does not require the suspension of therapy and changes in the patient's lifestyle</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental: Rivaroxaban + Diosmin + Stockings</title>
            <description>treatment of DVT with anticoagulation (rivaroxaban), elastic compression stockings and additional prescription of diosmin
Rivaroxaban: 15 mg b.i.d. for 3 weeks and then 20 mg q.d. up to 6 month
Diosmin: 600 mg q.d. for 12 month
compression stockings: above knee stocking for 12 month</description>
          </group>
          <group group_id="O2">
            <title>Control: Rivaroxaban + Stockings Only</title>
            <description>standard treatment of DVT with anticoagulation (rivaroxaban) and elastic compression stockings
Rivaroxaban: 15 mg b.i.d. for 3 weeks and then 20 mg q.d. up to 6 month
compression stockings: above knee stocking for 12 month</description>
          </group>
        </group_list>
        <measure>
          <title>Minor Bleeding</title>
          <description>any non-major or non-clinically relevant bleeding does not require the suspension of therapy and changes in the patient's lifestyle</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Study Group</title>
          <description>treatment of DVT with anticoagulation (rivaroxaban), elastic compression stockings and additional prescription of diosmin
Rivaroxaban: 15 mg b.i.d. for 3 weeks and then 20 mg q.d. up to 6 month
Diosmin: 600 mg q.d. for 12 month
compression stockings: above knee stocking for 12 month</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>standard treatment of DVT with anticoagulation (rivaroxaban) and elastic compression stockings
Rivaroxaban: 15 mg b.i.d. for 3 weeks and then 20 mg q.d. up to 6 month
compression stockings: above knee stocking for 12 month</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Clinically relevant non-major bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Minor bleeding</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dispesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Unsuspected high frequency of PTS in the Control group (standard treatment with rivaroxaban and compression stockings) led to early termination of enrollment (75% of planned sample size).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Kirill Lobastov</name_or_title>
      <organization>Pirogov Russian National Research Medical University</organization>
      <phone>+7-985-211-63-31</phone>
      <email>lobastov_kv@hotmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

